Kronos Bio
New York, US · Founded 2017 · Delaware corporation · 4 known investors
Biotech
Founders & leadership
RB
Rebecka Belldegrun, M.D.Director
OS
Otello Stampacchia, Ph.D.Director
DM
David M. TanenExecutive Officer, Director, Promoter
JC
John C. Martin, Ph.D.Director
NB
Norbert Bischofberger, Ph.D.Executive Officer, Director
AS
Arie S. Belldegrun, M.D.Director
CW
Christopher WilfongExecutive Officer
JA
Joshua A. KazamDirector
Investors · 4
Reported raises · per SEC filings
Form D private placements▶$105MraisedJul 2019 · 50 investors · BiotechnologyRule 506(b)
▶$105MraisedJul 2019 · 50 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jacob LovenDirector
- Rebecka Belldegrun, M.D.Director
- Norbert Bischofberger, Ph.D.Executive Officer, Director
- John C. Martin, Ph.D.Director
- Philip GutryExecutive Officer
- David M. TanenExecutive Officer, Director, Promoter
- Sean AlgeoExecutive Officer
- Joshua A. KazamDirector
- Otello Stampacchia, Ph.D.Director
- Arie S. Belldegrun, M.D.Director
- Offering amount
- $105M
- Amount sold
- $105M
- Proceeds to insiders
- $360K
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$18MraisedJun 2018 · 32 investors · BiotechnologyRule 506(b)
▶$18MraisedJun 2018 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rebecka Belldegrun, M.D.Director
- Otello Stampacchia, Ph.D.Director
- David M. TanenExecutive Officer, Director, Promoter
- John C. Martin, Ph.D.Director
- Norbert Bischofberger, Ph.D.Executive Officer, Director
- Arie S. Belldegrun, M.D.Director
- Christopher WilfongExecutive Officer
- Joshua A. KazamDirector
- Offering amount
- $18M
- Amount sold
- $18M
- Proceeds to insiders
- $360K
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.